Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 205,330 shares, a decrease of 53.0% from the April 30th total of 437,078 shares. Based on an average daily trading volume, of 494,011 shares, the short-interest ratio is currently 0.4 days. Approximately 20.1% of the company’s shares are sold short.
Institutional Trading of Clearmind Medicine
An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC lifted its stake in shares of Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 9.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 224,378 shares of the company’s stock after purchasing an additional 18,445 shares during the period. AdvisorShares Investments LLC owned 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent quarter. Institutional investors and hedge funds own 96.05% of the company’s stock.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a research note on Saturday, May 23rd.
Clearmind Medicine Price Performance
NASDAQ:CMND traded up $1.13 during trading hours on Friday, reaching $3.58. 44,764,183 shares of the stock were exchanged, compared to its average volume of 443,681. The stock has a market cap of $3.65 million, a PE ratio of -0.02 and a beta of 0.87. Clearmind Medicine has a twelve month low of $2.10 and a twelve month high of $524.00. The firm has a 50 day moving average of $7.17 and a 200 day moving average of $25.52.
Clearmind Medicine (NASDAQ:CMND – Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($33.20) EPS for the quarter.
About Clearmind Medicine
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Featured Stories
- Five stocks we like better than Clearmind Medicine
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
- 5 Under-the-Radar AI Stocks to Watch in June
- 5 Best Growth Stocks for the Next 10 Years
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
